Collaboration Agreements (Tables)

3 Months Ended

Mar. 31, 2014

Collaboration Agreement [Abstract]

Collaboration revenue with related party

The collaboration revenue the Company earned from Sanofi, as detailed below, consisted primarily of reimbursement for research and development expenses that the Company incurred, the Company's share of losses in connection with Sanofi's commercialization of ZALTRAP^®, and revenue related to non-refundable up-front payments.

	Three months ended March 31,
Sanofi Collaboration Revenue	2014			2013
ZALTRAP:
Regeneron's share of losses in connection with commercialization of ZALTRAP	$	(3,212	)	$	(7,789	)
Reimbursement of Regeneron research and development expenses	1,092			2,089
Other	2,177			1,858
Total ZALTRAP	57			(3,842		)
Antibody:
Reimbursement of Regeneron research and development expenses	126,822			99,623
Other	3,629			3,492
Total Antibody	130,451			103,115
Total Sanofi collaboration revenue	$	130,508		$	99,273

Collaboration revenue

The collaboration revenue the Company earned from Bayer HealthCare is detailed below:

	Three months ended March 31,
Bayer HealthCare Collaboration Revenue	2014		2013
EYLEA:
Regeneron's net profit in connection with commercialization of EYLEA outside the United States	$	61,159	$	6,362
Sales milestones	30,000		—
Cost-sharing of Regeneron EYLEA development expenses	20,347		5,888
Other	10,932		2,657
Total EYLEA	122,438		14,907
PDGFR-beta antibody:
Cost-sharing of REGN2176-3 development expenses	513		—
Other	2,361		—
Total PDGFR-beta	2,874		—
Total Bayer HealthCare collaboration revenue	$	125,312	$	14,907